Details of the Drug Combination

General Information of Drug Combination (ID: DCQ9Q5Y)

Drug Combination Name

Terameprocol TEM

Indication

Disease Entry	Status	REF
Anaplastic large cell lymphoma	Investigative	[1]

Component Drugs

Terameprocol DMC3P45

TEM DMLNFWU

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: SR

Zero Interaction Potency (ZIP) Score: 1.41

Bliss Independence Score: 5.49

Loewe Additivity Score: 5.41

LHighest Single Agent (HSA) Score: 3.44

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Terameprocol

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]

Terameprocol Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Transcription factor Sp1 (SP1)	TTZEP6S	SP1_HUMAN	Modulator	[2]
------------------------------------------------------------------------------------

Indication(s) of TEM

Disease Entry	ICD 11	Status	REF
Postherpetic neuralgia	1E91.5	Phase 2	[3]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Renal cell carcinoma	DCZX1B5	UO-31	Investigative	[1]
Renal cell carcinoma	DCTLQYJ	SN12C	Investigative	[1]
Melanoma	DC3M1JX	SK-MEL-2	Investigative	[4]
------------------------------------------------------------------------------------

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2	Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030055)
4	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976